December 2014

Ctrials association is hosting a seminar: GCP Audits. Audits are a significant learning tool for improving the clinical development process throughout all its stages. The audit contributes to the level of certainty regarding the data quality and participants rights protection. During the seminar, experienced professionals will share their experience about the rationale and will offer practical tools for work. The seminar will take place at the Sourasky medical center in Tel Aviv (Ichilov) on Monday February 9, 2015 (Hebrew). 
A record nine (and a half) Israeli biomed companies held IPOs on Nasdaq in 2014, showing the US capital market's extraordinary enthusiasm about young Israeli companies in the industry. The nine companies raised a total of $472 million (not including semi-Israeli company Kite Pharma, a story in itself), a very large sum for financing Israeli science and innovation. The effect went beyond the offerings themselves; there was no Israeli pharmaceutical company in 2014 that did not consider, at least internally or informally, the possibility of greener grass on the other side of the ocean.
Policy change: 0% VAT is coming to the field of clinical trialsVAT amendment lowering the cost of clinical trials in humans: "everyone said it was the right thing". An amendment to the VAT is expected to improve the situation of international companies which conduct new clinical trials in Israel. The new law lowers the VAT on the provision of supervision and control of clinical trials to zero. In addition, the Ministry of Finance recently passed regulation reduces the Customs and VAT paid for importing drugs for clinical trials. Both changes will lower the cost of clinical trials to the European level. Sources involved in the subject believe that the move will increase the number of trials that are carried out in Israel. (Hebrew).
IATI Biomed May 12-14 Tel Aviv. IATI Biomed will be held May-14 in Tel Aviv. The conference is a meeting place for healthcare’s industry players from Israel and abroad. Exuberance is felt everywhere; lectures, exhibition halls and partnership meetings. International visitors come to witness the various innovations, and experience firsthand the entrepreneurial spirit so strongly exhibited within the vibrant Israeli life science community.
Israeli Startups Set Record for Exits in 2014. Israeli high-tech and biotech startups witnessed a record year of acquisitions and initial public offerings (IPOs), according to end-of-year reports by accounting firm PricewaterhouseCoopers (PwC) and Ethosia Human Resources. The reports show that 52 Israeli startups exited to the tune of some $15 billion this year, while 18 IPOs racked up $9.8 billion.